The Hallmarks of Aging, Explained (and Why They Matter)

Almost every longevity intervention you'll read about — senolytics, NAD+ boosters, rapamycin, fasting, even creatine — is pitched as targeting one or more "hallmarks of aging." That phrase isn't marketing fluff; it comes from a specific, influential scientific framework. Understanding it is the single best way to cut through longevity hype, because it lets you ask the only question that matters: which hallmark does this intervention claim to hit, and is there human evidence it actually does? This page is the plain-English map. It's the framework our other reviews keep referring back to — and it pairs directly with our pillar on longevity medicine: what's proven vs hyped.

Where the framework comes from

In 2013, a group of researchers led by Carlos López-Otín published a landmark Cell paper titled simply "The Hallmarks of Aging"¹. Borrowing the structure of the famous "hallmarks of cancer" papers, they proposed nine cellular and molecular processes that together drive aging across organisms. Their criteria were strict: each hallmark should appear during normal aging, accelerating it should speed aging up, and reversing or slowing it should slow aging down. A decade later, in 2023, the same group published an update, "Hallmarks of Aging: An Expanding Universe," which expanded the list to twelve by adding three more². Together these two papers are the reference frame for the entire field — when a clinic or supplement says it "targets aging," this is almost always the map it's pointing at.

The twelve hallmarks, in plain English

The 2023 framework groups the hallmarks loosely into three tiers: primary causes of damage, antagonistic responses that are protective at first but harmful in excess, and integrative hallmarks that emerge when the damage overwhelms the system². Here's each one, translated.

The primary hallmarks — the root damage:

• •Genomic instability. DNA accumulates damage over a lifetime; when repair can't keep up, mutations build up and cells malfunction.
• •Telomere attrition. The protective caps on the ends of chromosomes shorten each time a cell divides; when they get too short, the cell stops dividing or dies.
• •Epigenetic alterations. The chemical "tags" that control which genes are on or off drift with age, so cells express the wrong genes at the wrong time. (This drift is the basis of the "epigenetic clocks" used in biological-age tests.)
• •Loss of proteostasis. The cell's quality-control system for folding and clearing proteins degrades, letting damaged proteins accumulate — a feature of many age-related diseases.
• •Disabled macroautophagy. (New in 2023.) Autophagy — the cell's recycling of its own worn-out components — declines with age, so junk that should be cleared piles up.

The antagonistic hallmarks — protective, until they're not:

• •Deregulated nutrient sensing. The pathways that sense food and energy (involving insulin/IGF-1, mTOR, AMPK, and sirtuins) shift with age in ways that promote growth at the expense of maintenance. This is the pathway fasting, rapamycin, and metformin all aim at.
• •Mitochondrial dysfunction. The cell's power plants become less efficient and leakier with age, reducing energy and raising stress signals.
• •Cellular senescence. Damaged cells stop dividing but refuse to die, lingering and spewing inflammatory signals. Helpful in small amounts (it suppresses cancer and aids wound healing); harmful when senescent cells accumulate³.

The integrative hallmarks — the system-level failures:

• •Stem-cell exhaustion. The reserves of cells that regenerate tissues run down, so blood, muscle, gut, and other tissues repair themselves more slowly.
• •Altered intercellular communication. The signaling between cells goes awry — most notably a chronic, low-grade inflammation often nicknamed "inflammaging."
• •Chronic inflammation. (Elevated to its own hallmark in 2023.) Persistent low-grade inflammation that drives or worsens nearly every age-related disease.
• •Dysbiosis. (New in 2023.) Age-related shifts in the gut microbiome that affect metabolism, immunity, and inflammation.

Why the framework is useful — and where it's overstated

The hallmarks are powerful because they turn "aging" from a vague inevitability into a list of mechanisms you can in principle target. That's the foundation of the geroscience hypothesis — the idea that intervening on the shared biology of aging could delay many age-related diseases at once, rather than fighting them one by one⁴. It's a genuinely compelling research program.

But two honest caveats keep this site grounded. First, the hallmarks are interconnected, not independent — they feed back on each other, so cleanly fixing one in isolation rarely "reverses aging" the way a headline implies. Second, and more important: targeting a hallmark in a model organism is not the same as extending human healthspan. The strongest hallmark-based evidence is overwhelmingly in cells, mice, and other animals. Clearing senescent cells extends healthy lifespan in mice⁵ and improves physical function and survival in aged mice⁶; rapamycin, which acts on the nutrient-sensing mTOR pathway, extends lifespan in mice even when started late in life⁷; caloric restriction reduces age-related mortality in rhesus monkeys⁸. These are real, important results — and they are also exactly the kind of animal data that translates to humans far less reliably than the marketing suggests.

How to use the hallmarks to read longevity claims

Here's the practical payoff. When you encounter any longevity product or therapy, run it through three questions:

1. 1.Which hallmark does it claim to target? (If the answer is "all of them" or "aging generally," be skeptical.)
2. 2.What's the evidence it actually moves that hallmark — and in what species? A mouse lifespan result and a human outcome trial are worlds apart.
3. 3.Does moving the hallmark translate to a benefit you care about — living longer or healthier — rather than just shifting a biomarker?

That third question is where most of the field falls down, because a biomarker (a shorter telomere, a higher NAD+ level, an "epigenetic age") is a proxy, and proxies get sold as outcomes constantly. We walk through how that plays out across specific interventions in NAD+ for longevity, where the human data stop at "raises a marker," and in peptides for longevity, where mechanism dramatically outruns proof.

The bottom line

The hallmarks of aging — nine in 2013, twelve in 2023 — are the field's shared map of why we get old at the cellular level, and they're the framework nearly every intervention points to. They're genuinely useful: they let you ask which mechanism a therapy targets and demand evidence it does. But they're a map of mechanisms, not a guarantee of results. Most hallmark-targeting evidence lives in cells and animals, the hallmarks are tangled together, and "hits a hallmark" is a hypothesis about humans until a human trial says otherwise. Use the framework the way scientists intended — as a tool for asking sharper questions, not as a license to believe every "anti-aging" claim that name-drops it. For where these ideas meet real clinics and real price tags, see our graded best longevity clinics hub, and for the cheap, well-evidenced lever that actually targets stem-cell and muscle decline in humans, see creatine for aging.